Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirnaomics, a US-China RNAi Company, Completes $47 Million C Funding

publication date: Apr 26, 2019

Sirnaomics, a US-China company developing RNAi therapeutics against cancer and fibrotic diseases, completed a $22 million C2 round from China investors, bringing the total C funding to $47 million. The C2 round was led by CR-CP Life Sciences Fund, a Hong Kong JV formed by China Resources and Charoen Pokphand Group, two Asian conglomerates. Sirnaomics will use the proceeds to support clinical trials of its RNAi candidates, while it advances its technology platforms. Sirnaomics is headquartered in Maryland with China operations in Suzhou and Guangzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital